­

Doporučené postupy psychiatrické péče
Psychiatrické společnosti ČLS JEP

Stáhnout kapitolu v PDF

Autoři: Jiří Masopust, Miloslav Kopeček, Dita Protopopová

Garanti: Tomáš Kašpárek, Libor Ustohal

Oponent: Pavel Mohr

 

Stabilizační a udržovací léčba schizofrenie

Vysvětlivky:
ovál - nadpis 
kosočtverec - výběr z více variant
přerušovaná čára - diagram pokračuje na další straně 

Nežádoucí účinky navozené antipsychotiky

Tabulka 1 Relativní frekvence nejčastějších NÚ antipsychotik (upraveno Huhn et al. 2019, Taylor et al. 2021, Pillinger et al. 2020)

Tabulka 1

Data v tabulce slouží k rychlé orientaci pro lékaře, kteří s léčbou některým antipsychotikem začínají. Zde uvedené údaje nenahrazují zdroje dat z klinických studií.

Tabulka 2 - intervence u nežádoucích účinků navozených antipsychotiky

Tabulka 2

Literatura

Allenet B, Schmidlin S, Genty C, Bosson JL. Antipsychotic drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf. 2012;21(1):42-8.

Baskak B, Atbasoglu EC, Ozguven HD, Saka MC, Gogus AK.The effectiveness of intramuscular biperiden in acute akathisia: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2007;27(3):289-94.

Caemmerer J, Correll CU, Maayan L.Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res. 2012;140(1-3):159-68.

Correll CU, Maayan L, Kane J, Hert MD, Cohen D. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials. J Clin Psychiatry. 2016;77(6):e746-56.

de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016;16(1):341.

de Leon J, Sanz EJ, Norén GN, De Las Cuevas C. Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics. World Psychiatry. 2020;19(1):120-121.

DiMascio A, Bernardo DL, Greenblatt DJ, Marder JE. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry. 1976;33(5):599-602.

Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, Kulkarni J, McGorry P, Nielssen O, Tran N. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410-72.

Gopalakrishnan R, Jacob KS, Kuruvilla A, Vasantharaj B, John JK Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial. Am J Psychiatry. 2006;163(3):494-9.

Gugger JJ Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. CNS Drugs. 2011;25(8):659-71.

Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, Bäckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019; 394: 939-951.

Kalkavoura CS, Michopoulos I, Arvanitakis P, Theodoropoulou P, Dimopoulou K, Tzebelikos E, Lykouras L. Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. Exp Clin Psychopharmacol. 2013;21(4):332-41.

Kreinin A, Miodownik C, Mirkin V, Gaiduk Y, Yankovsky Y, Bersudsky Y, Lerner PP, Bergman J, Lerner V. ;Double-Blind, Randomized, Placebo-Controlled Trial of Metoclopramide for Hypersalivation Associated With Clozapine. J Clin Psychopharmacol. 2016;36(3):200-5.

Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol. 2006 r;21(2):99-103.

Kreinin A, Miodownik C, Sokolik S, Shestakova D, Libov I, Bergman J, Lerner V.Amisulpride versus moclobemide in treatment of clozapine-induced hypersalivation. World J Biol Psychiatry. 2011;12(8):620-6

Kopeček M, Masopust J, Hubeňák J, Wolná A, Hanka J, Racková S, Papežová S, Probst T. Brexpiprazol v klinické praxi aneb umění léčby směřující k funkční remisi schizofrenie. Česká a slovenská psychiatrie. 2021, 117(6), 283-289. ISSN 1212-0383.

Kutcher S, Williamson P, MacKenzie S, Marton P, Ehrlich M. Successful clonazepam treatment of neuroleptic-induced akathisia in older adolescents and young adults: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 1989;9(6):403-6.

Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, Samara M, Rabaioli M, Bächer S, Cipriani A, Geddes JR, Salanti G, Davis JM. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. Am J Psychiatry. 2017 May 25:appiajp201716121358. [Epub ahead of print]

Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-62.

Lima AR, Bacalcthuk J, Barnes TR, Soares-Weiser K. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2004, (4):CD001946.

Lin CC, Bai YM, Wang YC, Chen TT, Lai IC, Chen JY, Chen SY, Gau SS, Liou YJ. Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics. J Clin Psychopharmacol. 2009;29(6):529-36.

Lindenmayer JP, Tedeschi F, Yusim A, Khan A, Kaushik S, Smith RC, Parakadavil M. Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia. Clin Schizophr Relat Psychoses. 2012;5(4):185-92.

Liu Y, Xu J, Fang K, Xu Y, Gao J, Zhou C, Tang X, Fang X, Chen J, Xie C, Zhang F, Zhang X, Wang C. Current antipsychotic agent use and risk of venous thromboembolism and pulmonary embolism: a systematic review and meta-analysis of observational studies. Ther Adv Psychopharmacol. 2021;11:2045125320982720.

Maršálek M. Extrapyramidové polékové poruchy in Seifertová et al. Postupy v léčbě psychických poruch: algoritmy České neuropsychofarmakologické společnosti. Praha: Academia Medica Pragensis, 2008.

Masopust J, et al. Prospektivní sledování prevence tromboembolismu u imobilizovaných psychiatrických pacientů. Čes Slov Psychiat. 2010;106:337–342.

Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, Kales HC. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015;72(5):438-45.

Miodownik C, Lerner V, Statsenko N, Dwolatzky T, Nemets B, Berzak E, Bergman J. Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, double-blind, controlled study. Clin Neuropharmacol. 2006;29(2):68-72.

Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, Uchida H. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014;40(6):1385-403.

Mohr P, Kopeček M, Brunovská M, Páleníček T. Klinická psychofarmakologie. Maxdorf-Jessenius. 2017

Montejo AL, de Alarcón R, Prieto N, Acosta JM, Buch B, Montejo L. Management Strategies for Antipsychotic-Related Sexual Dysfunction: A Clinical Approach. J Clin Med. 2021;10(2):308.

Montes JM, Rodriguez JL, Balbo E, Sopelana P, Martin E, Soto JA, Delgado JF, Diez T, Villardaga I. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):383-8.

Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry. 2008;69(7):1046-56.

Nunes LV, Moreira HC, Razzouk D, Nunes SO, Mari Jde J. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. J Sex Marital Ther. 2012;38(3):281-301.

Paton C, Esop R. Managing clozapine-induced neutropenia with lithium. Psychiatric Bulletin 2005; 29: 186–188.

Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, Beck K, Natesan S, Efthimiou O, Cipriani A, Howes OD. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64-77.

Ponsford M, Castle D, Tahir T, Robinson R, Wade W, Steven R, Bramhall K, Moody M, Carne E, Ford C, Farewell D, Williams P, El-Shanawany T, Jolles S. Clozapine is associated with secondary antibody deficiency. Br J Psychiatry. 2018 Sep 27:1-7.

Poyurovsky M, Epshtein S, Fuchs C, Schneidman M, Weizman R, Weizman A. Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study. J Clin Psychopharmacol. 2003;23(3):305-8.

Pujalte D, Bottaï T, Huë B, Alric R, Pouget R, Blayac JP, Petit P. A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia. Clin Neuropharmacol. 1994;17(3):236-42.

Rathbone J, Soares-Weiser K Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2006 18;(4):CD003727.

Reinstein MJ, Sirotovskaya LA, Chasanov MA. Comparative Efficacy and Tolerability of Benzatropine and Terazosin in the Treatment of Hypersalivation Secondary to Clozapine. Clin. Drug Investig. (1999) 17: 97.

Seifertová D. Život ohrožující situace v Seifertová et al. Postupy v léčbě psychických poruch: algoritmy České neuropsychofarmakologické společnosti. Praha: Academia Medica Pragensis, 2008.

Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934-43.

Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA; Schizophrenia Trials Network. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry. 2011;168(9):947-56.

Stryjer R, Rosenzcwaig S, Bar F, Ulman AM, Weizman A, Spivak B Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study. Clin Neuropharmacol. 2010;33(5):219-22.

Sultan RS, Olfson M, Correll CU, Duncan EJ. Evaluating the Effect of the Changes in FDA Guidelines for Clozapine Monitoring. J Clin Psychiatry. 2017;78(8):e933-e939.

Švestka J. Clozapin: prototyp antipsychotik nové generace. 1998, Maxdorf, Praha.

Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry. 14th ed. Willey-Blackwell; 2021.

Terevnikov V, Stenberg JH, Tiihonen J, Burkin M, Joffe G. Add-on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first-generation antipsychotics. Nord J Psychiatry. 2017;71(1):77-80.

Tse L, Procyshyn RM, Fredrikson DH, Boyda HN, Honer WG, Barr AM. Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension. Int Clin Psychopharmacol. 2014;29(3):125-37.

Ustohal L, Baláž M. Léčba EPS - akutní a tardivní dystonie a dyskineze. Doporučené postupy psychiatrické péče Psychiatrické společnosti ČLS JEP 2018. [cit. 22.3.2022] Dostupné z: https://postupy-pece.psychiatrie.cz/lecba/dystonie-dyskineze/lecba-eps

Watt JA, Goodarzi Z, Veroniki AA, Nincic V, Khan PA, Ghassemi M, Thompson Y, Lai Y, Treister V, Tricco AC, Straus SE. Safety of pharmacologic interventions for neuropsychiatric symptoms in dementia: a systematic review and network meta-analysis. BMC Geriatr. 2020 16;20(1):212.

Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE.Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology. 2008;33(5):985-94.

Yoon HW, Lee JS, Park SJ, Lee SK, Choi WJ, Kim TY, Hong CH, Seok JH, Park IH, Son SJ, Roh D, Kim BR, Lee BO. Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study. Clin Neuropharmacol. 2016;39(6):288-294.

Yunusa I, Alsumali A, Garba AE, Regestein QR, Eguale T. Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis. JAMA Netw Open. 2019;2(3):e190828.

Zheng W, Wang S, Ungvari GS, Ng CH, Yang XH, Gu YH, Li M, Xiang YQ, Xiang YT. Amantadine for Antipsychotic-Related Weight Gain: Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin Psychopharmacol. 2017;37(3):341-346.

Reference

Baldez DP, Biazus TB, Rabelo-da-Ponte FD, Nogaro GP, Martins DS, Kunz M, Czepielewski LS. The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: Network meta-analyses of randomized controlled trials. Neurosci Biobehav Rev. 2021;126:265-275.

Balzan RP, Delfabbro PH, Galletly CA, et al. Metacognitive training for patients with schizophrenia: Preliminary evidence for a targeted, single-module programme. Australian and New Zealand Journal of Psychiatry 2014; 48: 1126–1136.


Barnes TR, Drake R, Paton C, Cooper SJ, Deakin B, Ferrier IN, Gregory CJ, Haddad PM, Howes OD, Jones I, Joyce EM, Lewis S, Lingford-Hughes A, MacCabe JH, Owens DC, Patel MX, Sinclair JM, Stone JM, Talbot PS, Upthegrove R, Wieck A, Yung AR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020;34(1):3-78.

British Psychological Society. New Ways of Working for Applied Psychologists in Health and Social Care – The End of the Beginning. Leicester: British Psychological Society, Leicester; 2007.

Cerveri G, Gesi C, Mencacci C. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatr Dis Treat 2019; 15:1525-1535.

Crawford MJ, Killaspy H, Barnes TR, et al. Group art therapy as an adjunctive treatment for people with schizophrenia: A ran- domised controlled trial (MATISSE). Health Technology Assessment 2012;16(8): iii–iv, 1–76.

Chilvers R, Macdonald G and Hayes A. Supported housing for people with severe mental disorders. The Cochrane Database of Systematic Reviews 2006; 4: CD000453.

Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, Kulkarni J, McGorry P, Nielssen O, Tran N. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 2016; 50: 410-472.

Galling B, Roldán A, Hagi K, Rietschel L, Walyzada F, Zheng W, Cao XL, Xiang YT, Zink M, Kane JM, Nielsen J, Leucht S, Correll CU. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry 2017; 16: 77-89.

Harvey, PD, Siu, CO, Hsu, J, Cucchiaro, J, Maruff, P, Loebel, A. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: A short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur. Neuropsychopharmacol. 2013;23:1373–1382.

Harvey, PD, Siu, CO, Ogasa,M, Loebel, A. Effect of lurasidone dose on cognition in patients with schizophrenia: Post-hoc analysis of a long-term, double-blind continuation study. Schizophr. Res. 2015;166:334–338.

Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, Bäckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019; 394: 939-951.

Kahn RS, Winter van Rossum I, Leucht S, McGuire P, Lewis SW, Leboyer M, Arango C, Dazzan P, Drake R, Heres S, Díaz-Caneja CM, Rujescu D, Weiser M, Galderisi S, Glenthøj B, Eijkemans MJC, Fleischhacker WW, Kapur S, Sommer IE; OPTiMiSE study group. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry. 2018;5(10):797-807.

Killaspy H, Kingett S, Bebbington P, Blizard R, Johnson S, Nolan F, et al. Randomised evaluation of assertive community treatment: 3-Year outcome. British Journal of Psychiatry 2009; 195: 81-82.

Kinoshita Y, Furukawa TA, Kinoshita K, et al. Supported employment for adults with severe mental illness. The Cochrane Database of Systematic Reviews 2013; 9: CD008297.

Komatsu, H., Y. Sekine, N. Okamura, N. Kanahara, K. Okita, S. Matsubara, T. Hirata, T. Komiyama, H. Watanabe and Y. Minabe. Effectiveness of Information Technology Aided Relapse Prevention Programme in Schizophrenia excluding the effect of user adherence: A randomized controlled trial. Schizophr Res 2013; 150: 240-244.

Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Nikolakopoulou A, Leucht S. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 2018; 268(7):625-639.Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166:152–163.

Kopeček M, Masopust J, Hubeňák J, Wolná A, Hanka J, Racková S, Papežová S, Probst T. Brexpiprazol v klinické praxi aneb umění léčby směřující k funkční remisi schizofrenie. Česká a slovenská psychiatrie. 2021; 117(6): 283-289.

Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, Samara M, Rabaioli M, Bächer S, Cipriani A, Geddes JR, Salanti G, Davis JM. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. Am J Psychiatry 2017;174:927-942.

Malone D, Marriott S, Simmonds S, Tyrer P, Malone D, Marriott S et al. Community mental health teams (CMHTs) for people with severe mental illnesses and distordered personality. Cochrane database of Systematic Reviews 2010; 3, Art. No. CD000270.

Marsh PJ, Langdon R, Harris A, et al. The case for social-cognitive remediation in schizophrenia: A life well lived is more than remission from psychosis. Australian and New Zealand Journal of Psychiatry 2013;47: 512–515.

Marshall M, Lockwood A. Assertive community treatment for people with severe mental disorders. Cochrane Database Syst Rev. , 2011;4:CD001089

Marshall, M, Rathbone, J. Early intervention for psychosis. Cochrane Database of Systematic Reviews 2011; (6). Retrieved from http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004718.pub3/abstract

Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S; International Suicide Prevention Trial Study Group.Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
Arch Gen Psychiatry 2003; 60(1): 82-91.

Mohr P, Masopust J, Kopeček M. Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy? Front Psychiatry. 2022 Jan 25;12:781946.

Mohr P, Masopust J. Lurasidon: Profil antipsychotika druhé generace. Psychiatrie 2019; 23(4): 197-204.

Naslund JA, Marsch LA, McHugo GJ, Bartels SJ. Emerging mHealth and eHealth interventions for serious mental illness: A review of the literature. J Ment Health 2015; 24 (5): 321 – 332.

Norman R, Lecomte T, Addington D, Anderson E. Canadian treatment guidelines on psychosocial treatment of schizophrenia in adults. The Canadian Journal of Psychiatry 2017; 62(9); 617-623

Orfanos S, Banks C, Priebe S. Are Group Psychotherapeutic Treatments Effective for Patients with Schizophrenia? A Systematic Review and Meta-Analysis. Psychother Psychosom 2015; 84: 241-249.

Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, Beck K, Natesan S, Efthimiou O, Cipriani A, Howes OD. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 2020; 7(1):64-77.

Pitt V, Lowe D, Hill S, et al. Consumer-providers of care for adult clients of statutory mental health services. The Cochrane Database of Systematic Reviews 2013;3: CD004807.

Říčan J, Krupčík O, Melicharová H, Benýšková A, Rektor J, Pěč O, Plecháček O. První vlna center duševního zdraví z pohledu kvantitativní evaluace i zkušenosti. Česká a Slovenská Psychiatrie. 2021; 117(5):230-243.

Sin J and Norman I Psychoeducational interventions for family members of people with schizophrenia: A mixed-method systematic review. Journal of Clinical Psychiatry 2013; 74: e1145–e1162.

Taipale H, Mittendorfer-Rutz E, Alexanderson K, Majak M, Mehtälä J, Hoti F, Jedenius E, Enkusson D, Leval A, Sermon J, Tanskanen A, Tiihonen J. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res 2018; 197:274-280.

Taipale H, Tanskanen A, Mehtälä J, Vattulainen P, Correll CU, Tiihonen J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19(1):61-68.

Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms.
Schizophr Res 2012; 134: 219-225.

Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 14th ed. West Sussex, United Kingdom: John Wiley & Sons. 2021;956.

Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtälä J, Hoti F, Jedenius E, Enkusson D, Leval A, Sermon J, Tanskanen A, Taipale H. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia. JAMA Psychiatry 2017; 74(7): 686-693.

Tiihonen J, Taipale H, Mehtälä J, Vattulainen P, Correll CU, Tanskanen A. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. JAMA Psychiatry. 2019;76(5):499-507.

Tosato S, Albert U, Tomassi S, Iasevoli F, Carmassi C, Ferrari S, Nanni MG, Nivoli A, Volpe U, Atti AR, Fiorillo A. A Systematized Review of Atypical Antipsychotics in Pregnant Women: Balancing Between Risks of Untreated Illness and Risks of Drug-Related Adverse Effects. J Clin Psychiatry 2017; 78(5):e477-e489.

Wykes T, Huddy V, Cellard C, et al. A meta-analysis of cognitive remediation for schizophrenia: Methodology and effect sizes. The American Journal of Psychiatry 2011; 168: 472–485.

Wykes T, Steel C, Everitt B, et al. Cognitive behavior therapy for schizophrenia: Effect sizes, clinical models, and methodological rigor. Schizophrenia Bulletin 2008;34: 523–537.

Xia J, Merinder LB and Belgamwar MR Psychoeducation for schizophrenia. The Cochrane Database of Systematic Reviews 2011; 6: CD002831.

Zheng W, Zheng YJ, Li XB, Tang YL, Wang CY, Xiang YQ, de Leon J. Efficacy and safety of adjunctive aripiprazole in schizophrenia: meta-analysis of randomized controlled trials. J Clin Psychopharmacol 2016;36:628-636.

Datum zveřejnění: 24.3.2022

­